Charles Schwab Investment Management Inc Lexicon Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,417,295 shares of LXRX stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,417,295

Previous 1,359,148 4.28%

Holding current value

$1.01 Million

Previous $2.28 Million 2.54%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.51 - $2.39 $87,801 - $138,971	58,147 Added 4.28%	1,417,295 $2.23 Million
Q2 2024 Aug 12, 2024	BUY	$1.54 - $2.28 $736,158 - $1.09 Million	478,025 Added 54.25%	1,359,148 $2.28 Million
Q1 2024 May 08, 2024	BUY	$1.3 - $3.58 $22,032 - $60,673	16,948 Added 1.96%	881,123 $2.11 Million
Q4 2023 Feb 06, 2024	BUY	$1.0 - $1.53 $12,254 - $18,748	12,254 Added 1.44%	864,175 $1.32 Million
Q3 2023 Nov 08, 2023	BUY	$1.06 - $2.33 $147,918 - $325,142	139,546 Added 19.59%	851,921 $928,000
Q2 2023 Aug 09, 2023	BUY	$2.15 - $3.49 $51,092 - $82,936	23,764 Added 3.45%	712,375 $1.63 Million
Q1 2023 May 11, 2023	SELL	$1.99 - $2.68 $14,584 - $19,641	-7,329 Reduced 1.05%	688,611 $1.67 Million
Q4 2022 Feb 13, 2023	BUY	$1.8 - $2.56 $60,231 - $85,662	33,462 Added 5.05%	695,940 $1.33 Million
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $442,153 - $781,745	227,914 Added 52.45%	662,478 $1.59 Million
Q2 2022 Aug 15, 2022	SELL	$1.31 - $2.69 $87,198 - $179,057	-66,564 Reduced 13.28%	434,564 $809,000
Q1 2022 May 13, 2022	BUY	$1.95 - $3.89 $24,784 - $49,441	12,710 Added 2.6%	501,128 $1.05 Million
Q4 2021 Feb 11, 2022	BUY	$3.81 - $6.16 $48,097 - $77,763	12,624 Added 2.65%	488,418 $1.93 Million
Q3 2021 Nov 16, 2021	BUY	$3.38 - $5.35 $20,584 - $32,581	6,090 Added 1.3%	475,794 $2.29 Million
Q2 2021 Aug 16, 2021	BUY	$4.12 - $5.87 $191,489 - $272,825	46,478 Added 10.98%	469,704 $2.16 Million
Q1 2021 May 17, 2021	BUY	$3.45 - $9.09 $308,568 - $813,009	89,440 Added 26.8%	423,226 $2.49 Million
Q4 2020 Feb 16, 2021	BUY	$1.05 - $3.67 $40,589 - $141,871	38,657 Added 13.1%	333,786 $1.14 Million
Q3 2020 Nov 13, 2020	BUY	$1.44 - $2.1 $16,178 - $23,593	11,235 Added 3.96%	295,129 $425,000
Q2 2020 Aug 14, 2020	BUY	$1.75 - $2.3 $30,101 - $39,562	17,201 Added 6.45%	283,894 $567,000
Q1 2020 May 15, 2020	BUY	$1.8 - $4.28 $6,917 - $16,448	3,843 Added 1.46%	266,693 $521,000
Q4 2019 Feb 07, 2020	BUY	$3.16 - $5.15 $99,347 - $161,910	31,439 Added 13.59%	262,850 $1.09 Million
Q3 2019 Nov 08, 2019	SELL	$1.2 - $6.66 $45,003 - $249,769	-37,503 Reduced 13.95%	231,411 $697,000
Q2 2019 Aug 09, 2019	BUY	$5.35 - $7.11 $19,709 - $26,193	3,684 Added 1.39%	268,914 $1.69 Million
Q1 2019 May 14, 2019	BUY	$4.36 - $7.94 $24,978 - $45,488	5,729 Added 2.21%	265,230 $1.48 Million
Q4 2018 Feb 14, 2019	SELL	$6.15 - $10.51 $41,475 - $70,879	-6,744 Reduced 2.53%	259,501 $1.72 Million
Q3 2018 Nov 13, 2018	BUY	$10.32 - $13.06 $259,898 - $328,903	25,184 Added 10.45%	266,245 $2.84 Million
Q2 2018 Aug 08, 2018	BUY	$7.8 - $13.69 $112,522 - $197,491	14,426 Added 6.37%	241,061 $2.89 Million
Q1 2018 May 07, 2018	BUY	$7.86 - $11.39 $55,633 - $80,618	7,078 Added 3.22%	226,635 $1.94 Million
Q4 2017 Jan 17, 2018	BUY	$8.77 - $12.28 $135,303 - $189,455	15,428 Added 7.56%	219,557 $2.17 Million
Q3 2017 Nov 13, 2017	BUY	$12.17 - $16.3 $2.48 Million - $3.33 Million	204,129	204,129 $2.51 Million

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Lexicon Pharmaceuticals, Inc. Transaction History